Advertisement

Related Videos

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Varsha Gandhi, PhD, on Ibrutinib

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Amit Sanyal, MD: A Clinician’s Perspective

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Advertisement

Advertisement




Jul
31
Today In Oncology
Rectal Cancer AI Identifies Patients Most Likely to Benefit From Irinotecan-Intensified Neoadjuvant Chemoradiotherapy
Beth Erickson, MD, FASTRO, Named ASTRO President-Elect
Monica Baskin Named Director of VCU Massey Comprehensive Cancer Center
Case Series Supports High-Dose Oral Vitamin D for Cancer Therapy–Related Skin Toxicities
MRI-Based T Staging Matches Traditional Clinical Staging in Localized Prostate Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo